I wrote about generic and specialty drug company Actavis plc (NYSE:ACT) a while back detailing the rumored love triangle between them, Allergan (NYSE:AGN), …
In a research report issued today, Roth Capital analyst Ed Arce downgraded shares of Durata Therapeutics (NASDAQ:DRTX) from Buy to Neutral, while maintaining his $23 …
In a research report issued yesterday, Roth Capital analyst Ed Arce maintained a Buy rating on Durata Therapeutics (NASDAQ:DRTX) and reduced his price …
In a research report issued today, Roth Capital analyst Ed Arce assigned a Buy rating on Durata Therapeutics (NASDAQ:DRTX) with a $26 price target, …
In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on Durata Therapeutics (NASDAQ:DRTX) with a $26 price …
Last week, July 30, Durata Therapeutics (DRTX) announced a commercialization agreement for Dalvance (dalbavancin) with Angelini across much of Southern and Eastern Europe, Russia and Turkey. The …
In reaction to Durata Therapeutics’s (DRTX) announcement that it has began shipping Dalvance to its distributors, Roth Capital analyst Ed Arce reaffirmed a …
In a research report released today, Roth Capital analyst Ed Arce raised his price target on Durata Therapeutics (DRTX) to $28 (from $24), while maintaining a Buy rating on the stock. The new price target …